PIM kinase inhibition induces epigenetically conditioned transcriptional changes, abnormal RNA splicing and DNA damage in diffuse large B-cell lymphoma cells
Year: 2026
Type: article
Abstract: Diffuse large B-cell lymphoma (DLBCL) is characterized by pronounced molecular heterogeneity and remains incurable in a substantial fraction of patients who relapse or develop refractory disease following standard chemoimmunotherapy. PIM kinases are constitutively active oncogenic serine/threonine kinases implicated in lymphoma pathogenesis, transcriptional control and cell viability. However, the detailed molecular mechanisms by which PIMs regulate transcriptional programs, RNA metabolism, and genome stability remain largely unknown. Here, we demonstrate that PIM kinases maintain interphase phosphorylation of histone H3 at serine 10 (H3S10ph). Genetic or pharmacological inhibition of PIM kinase family leads to a global reduction of H3S10ph and other active histone marks, impaired RNA polymerase II elongation, and widespread transcriptional repression. Integrated epigenomic and transcriptomic analyses reveal that PIM family inhibition preferentially affects gene networks involved in RNA metabolism, including RNA processing, splicing, and RNA methylation pathways. PIM1 proximity proteome analysis identified multiple splicing-related proteins, and PIM1 co-association with SF3B1, XAB2, and EDC3 was confirmed using co-immunoprecipitation. Functionally, PIM kinase inhibition induces extensive alternative mRNA splicing abnormalities, promotes the accumulation of RNA-DNA hybrids (R-loops), and triggers DNA damage-associated checkpoint responses. Consistent with these findings, in preliminary in vitro drug combination studies, PIM inhibition synergizes with DNA-damaging chemotherapy and targeted inhibitors of the DNA damage response. Collectively, our results implicate PIM kinases in the regulation of transcription, RNA metabolism, and genome stability in DLBCL and provide a preclinical rationale for further investigation of combinations of PIM inhibitors with DNA-damaging agents or DNA damage response inhibitors.
Source: Oncogene
Authors: Sonia Dębek, Dorota Komar, Filip Garbicz, Mariia Stepanechko, Aleksandra Żołyniak, Anna Paszek, Dominika Trzmiel, Ewa Kurtz, Julia Maroszek, Marcin Kaszkowiak, Dominik Cysewski, Nazli Serin, Patryk Górniak, Sabina Lichołai, Eliza Głodkowska-Mrówka, Anna Rams, Ewa Jabłońska, Bjoern Chapuy, Kristyna Kupcova, Ondrej Havranek, Ari Melnick, Michał Pawlak, Maciej Szydłowski, Przemysław Juszczyński
Institutions: Instytut Hematologii i Transfuzjologi, Centre for Omic Sciences, EURECAT Centre Tecnològic de Catalunya, Universitat Rovira i Virgili, Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Polish Academy of Sciences, Broad Institute, Massachusetts Institute of Technology, Medical University of Białystok, Humboldt-Universität zu Berlin, Stiftung Charité, Freie Universität Berlin, Charité – Universitätsmedizin Berlin, Charles University, General University Hospital in Prague, Josep Carreras Leukaemia Research Institute, Weill Cornell Medicine
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Keywords: PIM kinase inhibition, diffuse large B-cell lymphoma, histone H3 serine 10 phosphorylation, epigenetic regulation of transcription, RNA splicing, RNA-DNA hybrids, R-loops, RNA polymerase II elongation, RNA metabolism, genome stability, DNA damage response, SF3B1, drug synergy, DNA-damaging chemotherapy
Open Access status: hybrid
Estimated APC paid: $5,990
OpenAlex ID: W7236446721
